A Perth Amboy public hearing will be held March 5 to consider whether several Smith Street properties should be redeveloped ...

Viridian Therapeutics (NASDAQ:VRDN) shares shot up 25% in early trading Monday after the company reported positive topline results from a Phase 3 study of its drug veligrotug in the treatment of ...

Viridian Capital's latest report shows cannabis stocks pricing in no rescheduling or 280E relief, leaving MSOs stuck in ...

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian ...

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and ...

WALTHAM, Mass., January 08, 2025--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

Viridian Metals (TSXV: VRDN) announced Friday it has expanded its land position in Canada’s Labrador through staking, securing 2,600 km² of the prospective Seal Basin. This newly acquired ...

LOS ANGELES, Feb. 4, 2025 /PRNewswire/ -- Today, Dunn-Edwards Corporation announced its first-ever Color of the Century, Viridian Odyssey (DE1925), a deep, sophisticated shade of blue-green ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...